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ABSTRACT
Disclosed herein are methods and compositions of treating a
subject suffering from a wound. In exemplary examples, the
method involves elevating MCPIP levels in a subject in need.
Elevating MCPIP levels may involve direct administration
(e.g. delivery of protein) or indirect administration (e.g. delivery vehicle capable of increasing expression of MCPIP).
7 Claims, 4 Drawing Sheets
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MCPIP AS WOUND THERAPY

infection starts, the infection may be very difficult to reverse,
and amputation of the affected limb is common.

RELATED APPLICATIONS
BRIEF DESCRIPTION OF THE DRAWINGS
This application is a continuation of U.S. Ser. No. 13/804,
275 filed Mar. 14, 2013, now issued as U.S. Pat. No. 8,703,
703, which is a continuation-in-part of U.S. Ser. No. 12/539,
907 filed Aug. 12, 2009, now abandoned, which is a
continuation of U.S. Ser. No. 11/643,057 filed Dec. 20, 2006,
now abandoned, which are incorporated herein in their
entirety by reference.
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BACKGROUND
Generally, when the skin of an individual is torn, cut or
punctured (wounded), the body naturally reacts to regenerate
dermal and epidermal tissue to close the wound. The wound
regeneration process typically includes a set of complex biochemical events that take place in a closely orchestrated cascade to repair the damage. These events overlap in time, but
may be categorized into different phases, namely the inflammatory, proliferative, and remodeling phases.
In the inflammatory phase, bacteria and debris are phagocytized and removed, and factors are released that cause the
migration and division of cells involved in the proliferative
phase. In the proliferative phase, the principal steps include
angiogenesis, fibroplasias, granulation tissue formation, epithelialization, and wound contraction. Angiogeneis involves
the development of new capillary blood vessels for the wound
area to provide oxygen and nutrients to the healing tissue. In
fibroplasia and granulation tissue formation, fibroblasts grow
and form a new, provisional extracellular matrix (ECM) by
excreting collagen and fibronectin. In epithelialization, epithelial cells crawl across the wound bed to cover the bed. In
contraction, the wound is made smaller by the action of
myofibroblasts, which establish a grip on the wound edges
and contract themselves using a mechanism similar to that in
smooth muscle cells. When the cells' roles are close to complete, urmeeded cells undergo apoptosis.
It is known that a number of disease states hinder the
normal wound healing process. For example, individuals with
diabetes often experience problems with what are termed
"diabetic foot ulcers." Diabetic foot ulcers are sores or
wounds, typically, on the feet that typically occur in individuals having diabetes. Oftentimes, these diabetic ulcers occur as
a direct or indirect result of nerve damage in the feet of the
individual as the prolonged high blood sugar levels associated
with diabetes is linked with damage to the nerves in the feet.
Such nerve damage in the feet, referred to as peripheral neuropathy, can cause loss of sensation as well as cause deformities of the feet. Due to the loss of sensation, individuals
with peripheral neuropathy may hurt their feet by repetitive
minor trauma (e.g., by prolonged walking) or a single major
trauma (e.g., by scraping skin, stepping on objects, immersing feet in hot water, cutting toenails inappropriately, or wearing ill-fitting shoes), but nevertheless may not notice such
injuries. A further complication of diabetes is a reduction in
blood flow to the feet due to the arterial blockage or other
causes, thereby severely inhibiting the body's ability to
adequately provide complete the proliferative stage of wound
regeneration/healing described above. As a result, once the
skin of the foot is torn, cut, or punctured, the wound healing
process (e.g., the proliferative phase) may be inordinately
slow in repairing the wound. Further, once a serious wound
develops, the risk ofinfection is high as the individual's body
is simply unable to heal the wound. Even further, once an
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FIG. 1. Expression of MCPIP on scratch-induced wound
healing in HaCaT cells. (A) Cells were cultured to confluence
and transfected with GFP or MCPIP vectors for 48 hrs and
wounded by scratching. Cells were then incubated for the
indicated hours and photographed. (B) Quantification of
scratch-induced wound healing during 24 hrs after scratching.
FIG. 2. Knockdown of MCPIP inhibited migration of
HaCaT cells. (A) HaCaT cells were cultured and transfected
with MCPIP siRNA or non-targeted siRNA for 48 hrs, RTPCR was performed to confirm that siRNA efficiently knockdown of MCPIP mRNA levels. (B) Cells were cultures to
confluence and wounded by scratching. Cells were then incubated for the indicated hours and photographed. (C) Quantification of cell migration during 24 h after scratching.
FIG. 3. Lack ofMCPIP impaired wound healing in MCPIP
KO mice. (A) Wound sites were photographed at the indicated time. (B) Changes in percentage of wound area at each
time point compared with the original wound area.
FIG. 4. Expression ofMCPIP enhanced wound healing in
diabetic mice. (A) Induction of MCPIP was found in the
wound skin but not in the healed skin. (B) Wound sites were
photographed at the indicated time. Day 0 pictures were taken
immediately after the wound. (C) Changes in percentage of
wound area at each time point compared with the original
wound area. (D) Expression of cytokines in wound skins at
day 12 after wound. (F) Expression of PECAM and VEGF in
wound skins at day 12 was examined by RT-PCR.
DETAILED DESCRIPTION
The inventors have previously identified the novel transcription factor designated as MCPIP (MCP-1-induced protein). MCPIP was initially isolated from human monocytes
after stimulation with MCP-1. The nucleotide (SEQ ID NO:
1) and amino acid (SEQ ID NO: 2) sequences of isolated
human MCPIP were deposited with GenBank under accession number AY920403 and the nucleotide (SEQ ID NO: 3)
and amino acid (SEQ ID NO: 4) sequences of isolated mouse
MCPIP were deposited with GenBank under accession number AY920404. The inventors have continued to study the
biological relevance of these genes/proteins, and to develop
new therapies based on this research. The invention is based
on the inventors discovery that maintaining or elevating
MCPIP levels can accelerate wound healing in a subject.
According to one embodiment, the invention pertains to a
method of treating wounds. MCPIP may be elevated by direct
administration of a composition. The composition may comprise a therapeutically effective amount of the MCPIP protein. The MCPIP protein composition may comprise a pharmaceutically acceptable excipient. Alternatively, MCPIP
may be elevated by administering a composition comprising
a delivery vehicle that results in the in vivo expression of
MCPIP. In yet another embodiment, MCPIP is elevated by
inducing expression of the endogenous gene.
As used herein, the use of the word "a" or "an" when used
in conjunction with the term "comprising" in the claims and/
or the specification may mean "one," but it is also consistent
with the meaning of"one or more," "at least one," and "one or
more than one."
The term "wound" as used herein refers to any break in the
epithelium resulting from a cut, abrasion, adhesion, surgical
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incision, thermal, chemical, or friction bum, ulcer, or the like,
as a result of an accident, incident, surgical procedure, or the
like. Wound can be further defined as acute and/or chronic.
Compositions of the present invention have been found to be
particularly useful in the treatment of diabetic ulcers, which
are a type of wound as defined herein.
The term "pharmaceutical composition" as used herein
refers to a wound composition as described herein that this
dispersed in a pharmaceutically acceptable carrier.
The term "subject" as used herein refers to any human or
nonhuman mammalian animal to which a wound composition is administered according to the methods described
herein. In a specific embodiment, the compositions and methods of the present invention are employed to treat a human
subject.
The term "effective amount" or "therapeutically effective
amount" as used herein refer to an amount effective, at dosages and for periods of time necessary to achieve a desired
result. The desired result may be an improvement in the
wound healing process (e.g., by reducing a surface area of the
wound), remediation of the symptoms of the wound (e.g.,
pain, infection, and the like), shortening of the duration of any
stage in the wound healing process, stabilization of the state
of wound (e.g., infection), prevention or slowing of the development of wound progression, prevention of, delay or slowing of wound progression, delay or slowing of wound onset,
amelioration or palliation of the wound state, and remission
(whether partial or total), whether detectable or undetectable.
The term "topical administration" as used herein includes
the contact of the wound compositions of the present invention with tissue on or about the wound area.
The term "parenteral administration" as used herein
includes any form of administration in which a composition is
delivered or absorbed into the patient without involving
absorption via the intestines. Exemplary parenteral administrations that are used in the present invention include, but are
not limited to intradermal or subcutaneous administration.
The term "treating" and "treatment" as used herein refers to
an approach for obtaining beneficial or desired results,
including clinical results. Beneficial or desired clinical results
can include, but are not limited to, an improvement in the
wound healing process (e.g., by reducing a surface area of the
wound), remediation of the symptoms of the wound (e.g.,
pain, infection, and the like), shortening of the duration of any
stage in the wound healing process or the overall wound
healing process, stabilization of infection (if any), and remission (whether partial or total), whether detectable or undetectable.
Compounds and Compositions
The compounds described herein may be provided in any
suitable form for administration to a wound of a patient. In
one embodiment, the compounds are provided as pharmaceutical composition comprising a pharmaceutically acceptable
carrier. In a typical embodiment, the compound is MCPIP or
a variant or derivative thereof.
In one aspect, the pharmaceutically acceptable carrier may
comprise a substrate, such as a natural or synthetic nonwoven or woven material, having the Compounds disposed
on and/or therein to define a dressing that can be applied to,
about, or adjacent to a wound. The substrate defining the
dressing may be selected from the group consisting of a
transdermal patch, a pad, a powder, a bandage, a host matrix,
or any other suitable substrate configured to be applied to,
over, and/or adjacent the wound. In certain embodiments, the
dressing comprising the Compounds may be a hemostatic
dressing as is known in the art. Exemplary hemostatic dressings are described in US Published Patent Application No.

20120282320, the entirety of which is hereby incorporated by
reference. The Compounds may be impregnated within, otherwise dispersed within, and/or applied to a surface of the
dressing using any suitable technique known in the art, such
as by coating, spraying or dipping. It is appreciated that the
dressing may include a polymeric coating or surface to be
placed in contact with the wound, such as Teflon®, to avoid
sticking of the dressing to the wound.
In addition, the wound compositions of the present invention may be provided and/or manufactured as a pharmaceutical composition for topical administration, parenteral
administration, and/or any other suitable administration. It is
understood that the active ingredient(s) and pharmaceutically
acceptable carrier may be provided individually (with or
without instructions for future mixing) or together (mixed,
non-mixed, or with instructions for future mixing) in the
respective formulation. Further, the wound composition may
be prepared by known methods for the preparation of pharmaceutically acceptable compositions suitable for administration to a patient, such that an effective quantity of the active
ingredients is combined in a mixture with a pharmaceutically
acceptable carrier. Suitable pharmaceutically acceptable carriers are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack
Publishing Company, Easton, Pa., USA 1985).
In one embodiment, the wound composition is provided in
the form of a topical composition that can be applied to, over,
or adjacent the wound area. Without limitation, the topical
composition may be in the form of a solution, a suspension, a
spray, a cream, a gel, a foam, an ointment, a lotion, or a
powder. The wound composition may be formulated as a
controlled release, delayed release, or a sustained release
formulation as is known in the art.
When a wound composition of the present invention is
provided in the form of a topical composition, the wound
composition may further include other cosmetic ingredients
and pharmaceutically acceptable topical carriers which have
substantially non-irritating, skin compatible components.
Such suitable cosmetic and pharmaceutical agents include,
but are not limited to, moisturizers, stabilizers, preservatives,
antiseptics, lubricants, humectants, gelling agents, chelating
agents, skin penetration enhancers, emollients, colorants, solvents, fatty bodies, thickening agents, emulsifiers, and/or any
other excipient(s ), which do not alter the therapeutic effect of
the active ingredient(s) therein, e.g., Compounds.
In certain embodiments, the pharmaceutically acceptable
carrier may include one or more of emulsifying agents, inert
carriers including hydrocarbon bases, emulsifying bases,
non-toxic solvents or water-soluble bases. Particularly suitable examples include pluronics, HPMC, CMC and other
cellulose-based ingredients, lanolin, hard paraffin, liquid paraffin, soft yellow paraffin or soft white paraffin, white beeswax, yellow beeswax, cetostearyl alcohol, cetyl alcohol,
dimethicones, emulsifying waxes, isopropyl myristate,
microcrystalline wax, oleyl alcohol and stearyl alcohol.
Exemplary topical formulations to which the Nanoparticles may be included are set forth in U.S. Published Patent
Application No. 20120289579, the entirety of which is
hereby incorporated herein. It is appreciated that the active
ingredient(s) described herein, e.g., Compounds, could
replace or augment the active ingredient(s) described in U.S.
Published Patent Application No. 20120289579.
The concentration of active compound in the pharmaceutical composition will depend on absorption, inactivation and
excretion rates of the active compound, the physicochemical
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characteristics of the compound, the dosage schedule, and
amount administered as well as other factors known to those
of skill in the art.
Typically a therapeutically effective dosage should produce a serum concentration of active compound of from about
0.1 ng/ml to about 50-100 µg/ml. The pharmaceutical compositions typically should provide a dosage of from about
0.001 mg to about 2000 mg of compound per kilo-gram of
body weight per day. Pharmaceutical dosage unit forms are
prepared to provide from about 1 mg to about 1000 mg and
preferably from about 10 to about 500 mg of the essential
active ingredient or a combination of essential ingredients per
dosage unit form.
The active compound may be administered at once, or may
be divided into a number of smaller doses to be administered
at intervals of time. It is understood that the precise dosage
and duration of treatment is a function of the disease being
treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test
data. It is to be noted that concentrations and dosage values
may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular
subject, specific dosage regimens should be adjusted over
time according to the individual need and the professional
judgment of the person administering or supervising the
administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not
intended to limit the scope or practice of the claimed compositions.
Preferred pharmaceutically acceptable derivatives include
acids, bases, enol ethers and esters, salts, esters, hydrates,
solvates and prodrug forms. The derivative is selected such
that its pharmacokinetic properties are superior to the corresponding neutral compound.
Thus, effective concentrations or amounts of one or more
of the compounds described herein or pharmaceutically
acceptable derivatives thereof are mixed with a suitable pharmaceutical carrier or vehicle for systemic, topical or local
administration to form pharmaceutical compositions. The
concentration of active compound in the composition will
depend on absorption, inactivation, excretion rates of the
active compound, the dosage schedule, amount administered,
particular formulation as well as other factors known to those
of skill in the art.
Applications
The compositions and methods described herein may be
utilized to promote the healing of any type of wound. The
wound may include any disruption in the integrity of the skin
or tissue as a result of: an external force (e.g., trauma); a
disease or condition; aging; a burn resulting from exposure to
sunlight, heat, and/or chemical reaction, for example; and/or
as a result from damage by internal physiological processes.
The wound may be open or closed. Further, the wound may be
characterized as a non-healing wound, which includes but is
not limited to incomplete healing wounds, and chronic
wounds. Incomplete healing wounds have healed to a certain
extent, but not to the extent expected for the time duration
involved, or have not begun healing as expected for the time
duration involved.
In certain embodiments, the wound is a chronic wound,
which may be defined as a wound that has not healed within
three months. Exemplary chronic wounds may include arterial ulcers, bum ulcers, decubitus ulcers, diabetic ulcers, diabetic foot ulcers, infectious ulcers, pressure ulcers, traumainduced ulcers, ulcerations associated with pyoderma
gangrenosum, venous ulcers, venous stasis ulcers, and vasculitic ulcers. It is appreciated that the wound may be asso-

ciated with a particular disorder or condition, which renders
the subject susceptible to, indirectly causes, or directly causes
a non-healing wound. In certain embodiments, the subject is
a diabetic, for example.
Kits
The compositions described herein may be provided in
suitable packaging for maintaining the integrity of the article.
In addition, the article may be provided as a kit along with
suitable instructions that direct a user to use of a wound
composition, e.g., pharmaceutical composition or dressing,
comprising the Compounds in the treatment of a wound in a
subject. The instructions may comprise user-readable and/or
computer-readable information embodied on any suitable
medium, such as a paper insert or a computer-readable disc.
Alternatively, the instructions may direct the user to an external source, such as to a website, where such instructions may
be found.
Dosing
One skilled in the art would readily appreciate that the
administration, duration, and dosing of the wound compositions may be determined or adjusted based on the age, body
weight, general condition, sex, diet, the severity of the wound,
and/or degree of inflammation and/or infection associated
with the wound. Effective amounts of the wound composition
can be given repeatedly, depending upon the effect of the
initial treatment regimen. Administrations are typically given
periodically, while monitoring any response. It will be recognized by a skilled person that lower or higher dosages or
number of applications other than those indicated herein may
be given, according to the administration schedules and
routes selected. In certain embodiments, the compounds may
be provided in a composition, such as a topical composition
or an injectable composition, in a concentration of at least 1
µM, and in particular embodiments, at least 10 µM.
In an embodiment, the wound compositions may be administered at least once daily for at least a first week's time.
Thereafter, the wound compositions may be applied to the
wound at greater intervals, such as once a week, until such
time as the wound is satisfactorily healed. In one embodiment, a wound composition is applied once a week (after the
initial daily application) for a period of at least seven weeks.
It is understood that prior to each application, the wound may
be rinsed with a sterile solution, such as saline, and allowed to
dry. Thereafter, a wound composition may be applied.
Conjunctive Agents
In accordance with another aspect, the wound compositions comprising Compounds described herein may be
employed alone in the treatment, or may be combined with a
conjunctive agent, which is administered to the patient independently of the wound composition or as part of the same
formulation. Such conjunctive agents may be delivered
simultaneously, before and/or after the administration of the
wound composition. Suitable conjunctive agents may
include, by way of example only, vasodilators, vasoconstrictors, hypertensive agents, antibacterial agents, antibiotics,
antioxidants, antifungal agents, non-steroidal antiinflammatory agents, steroidal agents, anesthetics, and/or diabetes
agents.
Suitable vasodilators include, but are not limited to, manidipine, nicardipine, nilvadipine, nisoldipine, nitrendipine,
benidipine, amlodipine, aranidipine, budralazine, cadralazine, ecarazine, hydralazine, todralazine, oxyphedrine, diltiazem, tolazoline, hexobendine, bamethan, clonidine, methyldopa, guanabenz, and the like.
Suitable vasoconstrictors include, but are not limited to,
dopamine, dobutamine denopamine and the like.
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Suitable hypertensive agents include, but are not limited to,
dopamine, dobutamine, denopamine, digitoxin, digoxin,
methyldigoxin, lanatoside C, G-strophantin, and the like.
Suitable antibacterial agents include, but are not limited to,
sulfonamides, such as sulfamethizole, sulfisoxazole, sulfamonomethoxin, sulfamethizole, salazosulfapyridine, silver
sulfadiazine, and the like, and quinolones, such as nalidixic
acid, pipemidic acid trihydrate, enoxacin, norfloxacin,
ofloxacin, tosufloxacin tosilate, ciprofloxacin hydrochloride,
lomefloxacinhydrochloride, sparfloxacin, fleroxacin, and the
like.
Suitable antibiotics include, but are not limited to, tetracyclin hydrochloride, ampicillin, piperacillin, gentamycin,
dibekacin, kanendomycin, lividomycin, tobramycin, amikacin, fradiomycin, sisomicin, tetracyclin, oxytetracyclin, rolitetracyclin, doxycyclin, ampicillin, piperacillin, ticarcillin,
cefalotin, cefapirin, cefaloridine, cefaclor, cefalexin, cefroxadine, cefadroxil, cefamandole, cefotoam, cefroxime, cefotiam, cefotiam hexetil, cefuroxime axetil, cefdinir, cefditoren
pivoxil, ceftazidime, cefpiramide, cefsulodin, cefinenoxime,
cefpodoxime proxetil, cefpirome, cefozopran, cefepime, cefsulodin, cefinenoxime, cefinetazole, cefminox, cefoxitin, cefbuperazone, latamoxef, flomoxef, cefazolin, cefotaxime,
cefoperazon, ceftizoxime, moxalactam, thienamycin, sulfazecin, azthreonam and their salts, griseofulvin, lankacidin
[J. Antibiotics, 38, 877-885 (1985)], and the like.
Suitable antioxidants may include, but are not limited to,
superoxide dismutase Vitamin C (Ascorbic Acid), Vitamin D,
Vitamin E, a-lipoic Acid, metronidazole, elemental antioxidants, ~-glucan, curcumin, epigallocatechin gallate, proanthocyanidins, propolis, honey, and the like.
Suitable antifungal agents include, but are not limited to,
polyene-based antibiotics (e.g., amphotericin B, nystatin, trichomycin); griseofulvin, pyrrolnitrin, and the like; cytosine
metabilism antagonists (e.g., flucytosine); imidazole derivatives (e.g., econazole, clotrimazole, miconazole nitrate,
bifonazole, croconazole); triazole derivatives (e.g., fluconazole, itraconazole, azole-based compounds, e.g., [2-[(lR,
2R)-2-(2,4-difluorophenyl)-2-hydroxy- l-methyl-3-(1 H-1,2,
4-t-riazol-1-yl)propyl]-4-[ 4-(2,2,3,3-tetrafluoropropoxy)
phenyl-3-(2H,4H)-1,2,-4-triazolone ); thiocarbamic acid
derivatives (e.g., trinaphthol); echinocandin-based derivatives (e.g., caspofamgine, FK-463, V-Echinocadin), and the
like.
Suitable non-steroidal antiinflammatory agents include,
but are not limited to, acetaminophen, fenasetin, ethenzamide, sulpyrine, antipyrine, migrenin, aspirin, mefenamic
acid, flufenamic acid, diclofenac sodium, loxoprofen sodium,
phenylbutazone, indomethacin, ibuprofen, ketoprofen,
naproxen, oxaprozin, flurbiprofen, fenbufen, pranoprofen,
floctafenine, epirizol, tiaramide hydrochloride, zaltoprofen,
gabexate mesilate, camostat mesilate, ulinastatin, colchicine,
probenecid, sulfinpyrazone, benzbromarone, allopurinol,
sodium gold thiomalate, sodium hyaluronate, sodium salicylate, morphine hydrochloride, salicylic acid, atropine, scopolamine, morphine, pethidine, levorphanol, ketoprofen,
naproxen, oxymorphone, and their salts.
Suitable steroidal agents include, but are not limited to,
dexamethasone, hexestrol, methimazole, betamethasone, triamcinolone, triamcinolone acetonide, fluorocinonide, fluorocinolone acetonide, prednisolone, methylprednisolone,
cortisone acetate, hydrocortisone, fluorometholone, beclometasone dipropionate, estriol, and the like.
Suitable anesthetics include, but are not limited to, cocaine
hydrochloride, procaine hydrochlodie, lidocaine, dibucaine
hydrochloride, tetracaine hydrochloride, mepivacaine hydrochloride, bupivacaine hydrochloride, oxybuprocaine hydro-

chloride, ethyl aminobenzoate, oxethazaine, and the like, or
other systemic, inhalation, or intravenous anesthetics.
Suitable diabetes agents include, but are not limited to,
actos, lodiglitazon, kinedak, penfill, humalin, euglucon,
glimicron, daonil, novolin, monotard, insulins, glucobay,
dimelin, rastinon, bacilcon, deamelin S, Iszilins]; hypothyroidism treating agent [dried thyroid gland (thyreoid),
levothyroxine sodium (thyradin S), liothyronidin sodium
(thyronine, thyromin), and the like.
The ratio between a compound of the present invention and
a conjunctive agent in a concomitant formulation may be
selected appropriately on the basis of the target, route, and
disease/condition of the patient and may be readily determined by one skilled in the art. In a particular embodiment,
the present invention includes a method of treating a wound
comprising administering to a patient in need thereof a wound
composition comprising an effective amount of Compounds
with an effective amount of an antibiotic to aid in combating
wound infection.
Alternative Modes of Administration
The compounds for use in the method of the invention are
typically formulated for topical or local administration but
can also be formulated for oral, transdermal, sub lingual, buccal, parenteral, rectal, intranasal, intraocular, intrabronchial
or intrapulmonary administration. For oral administration the
compounds can be of the form of tablets or capsules prepared
by conventional means with pharmaceutically acceptable
excipients such as binding agents (e.g., polyvinylpyrrolidone,
hydroxypropylcellulose or hydroxypropylmethylcellulose);
fillers (e.g., cornstarch, lactose, microcrystalline cellulose or
calcium phosphate); lubricants (e.g., magnesium stearate,
talc, or silica); disintegrates (e.g., sodium starch glycollate);
or wetting agents (e.g., sodium lauryl sulphate). If desired, the
tablets can be coated using suitable methods and coating
materials such as OPADRY film coating systems available
from Colorcon, West Point, Pa. (e.g., OPADRY, OY Type,
OY-C Type, Organic Enteric OY-P Type, Aqueous Enteric
OY-A Type, OY-PM Type and OPADRY® White,
32K18400).
In a particular embodiment, the oral form is a tablet containing MCPIP and a pharmaceutically acceptable excipient,
such as, but not limited to, mannitol, corn starch, microcrystalline cellulose, colloidal silicon dioxide, polyvinyl pyrrolidone, talc, magnesium stearate, and the like which are optionally coated with an OPADRY film coating.
Liquid preparation for oral administration can be in the
form of solutions, syrups or suspensions. The liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents
(e.g., sorbitol syrup, methyl cellulose or hydrogenated edible
fats); emulsifying agent (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol);
and preservatives (e.g., methyl or propyl p-hydroxy benzoates or sorbic acid).
For buccal administration, the compounds for use in the
method of the invention can be in the form of tablets or
lozenges formulated in a conventional manner.
For parenteral administration, the compounds for use in the
method of the invention can be formulated for injection or
infusion, for example, intravenous, intramuscular or subcutaneous injection or infusion, or for administration in a bolus
dose and/or continuous infusion. Suspensions, solutions or
emulsions in an oily or aqueous vehicle, optionally containing other formulatory agents such as suspending, stabilizing
and/or dispersing agents can be used.
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For rectal administration, the compounds for use in the
method of the invention can be in the form of suppositories or
enemas.
For sublingual administration, tablets can be formulated in
conventional manner.
For intranasal, intraocular, intrabronchial or intrapulmonary administration, conventional formulations can be
employed.
Further, the compounds (e.g. protein or delivery vehicle)
for use in the method of the invention can be formulated in a
sustained release preparation. For example, the compounds
can be formulated with a suitable polymer or hydrophobic
material which provides sustained and/or controlled release
properties to the active agent compound. As such, the compounds for use the method of the invention can be administered in the form of microparticles for example, by injection
or in the form of wafers or discs by implantation.
Delivery Vehicles
1) Viral Vectors
In accordance with the method of the invention, an expression vector is a viral or a non-viral expression vector. Viral
expression vectors which may be used advantageously in the
method of the invention include, but are not limited to, an
adeno associated virus (AAV) vector, a lentivirus vector, an
adenovirus vector, and a herpes simplex virus (HSY) vector.
In a preferred embodiment, the compositions of the invention can be tailored to include a nucleic acid sequence (e.g.,
SEQ ID NO: 1, derivatives, fragments and variants thereof) in
an expression vector. Viral vectors for use in the invention are
those that exhibit low toxicity to a host cell. Viral vector
methods and protocols that may be used in the invention are
reviewed in Kay et al. Nature Medicine 7:33-40, 2001. The
use of specific vectors, including those based on adenoviruses, adeno-associated viruses, herpes viruses, and retroviruses are described in more detail below.
The use of recombinant adenoviruses as vectors is discussed in W. C. Russell, Journal of General Virology
81:2573-2604, 2000; and Bramson et al., Curr. Opin. Biotechnol. 6:590-595, 1995. Adenovirus vectors are preferred
for use in the invention because they (1) are capable of highly
efficient gene expression in target cells and (2) can accommodate a relatively large amount ofheterologous (non-viral)
DNA. A preferred form of recombinant adenovirus is a "gutless", "high-capacity", or "helper-dependent" adenovirus
vector. Such a vector features, for example, (1) the deletion of
all or most viral-coding sequences (those sequences encoding
viral proteins), (2) the viral inverted terminal repeats (ITRs)
which are sequences required for viral DNA replication, (3)
up to 28-32 kb of"exogenous" or "heterologous" sequences
(e.g., sequences encoding an ammonia producing enzyme),
and (4) the viral DNA packaging sequence which is required
for packaging of the viral genomes into infectious capsids.
For specifically targeting liver, preferred variants of such
recombinant adenoviral vectors contain tissue-specific
enhancers and promoters operably linked to for example,
SEQIDNO: 1.
Other viral vectors that might be used in the invention are
adeno-associated virus (AAV)-based vectors. AAV-based
vectors are advantageous because they exhibit high transduction efficiency of target cells and can integrate into the host
genome in a site-specific manner. Use of recombinant AAV
vectors is discussed in detail in Tai, J., J. Biomed. Sci. 7:279291, 2000 and Monahan and Samulski, Gene Therapy 7:2430, 2000. A preferred AAV vector comprises a pair of AAV
inverted terminal repeats which flank at least one cassette
containing a tissue (e.g., gum)- or cell-specific promoter
operably linked to a urease nucleic acid. The DNA sequence

of the AAV vector, including the ITRs, the promoter and, for
example, urease gene may be integrated into the host genome.
The use of herpes simplex virus (HSV)-based vectors is
discussed in detail in Cotter and Robertson, Curr. Opin. Mo!.
Ther. 1:633-644, 1999. HSY vectors deleted of one or more
immediate early genes (IE) are advantageous because they
are generally non-cytotoxic, persist in a state similar to
latency in the host cell, and afford efficient host cell transduction. Recombinant HSY vectors can incorporate approximately 30 kb ofheterologous nucleic acid. A preferred HSY
vector is one that: (1) is engineered from HSY type I, (2) has
its IE genes deleted, and (3) contains a tissue-specific promoter operably linked to a urease nucleic acid. HSY amplicon
vectors may also be useful in various methods of the invention. Typically, HSY amplicon vectors are approximately 15
kb in length, and possess a viral origin of replication and
packaging sequences.
Retroviruses such as C-type retroviruses and lentiviruses
might also be used in the invention. For example, retroviral
vectors may be based on murine leukemia virus (MLV). See,
e.g., Hu and Pathak, Pharmacol. Rev. 52:493-511, 2000 and
Fong et al., Crit. Rev. Ther. Drug Carrier Syst. 17: 1-60, 2000.
MLV-based vectors may contain up to 8 kb ofheterologous
(therapeutic) DNA in place of the viral genes.
Additional retroviral vectors that might be used are replication-defective lentivirus-based vectors, including human
immunodeficiency (HIV)-based vectors. See, e.g., Vigna and
Naldini, J. Gene Med. 5:308-316, 2000 and Miyoshi et al., J.
Viral. 72:8150-8157, 1998. Lentiviral vectors are advantageous in that they are capable ofinfecting both actively dividing and non-dividing cells. They are also highly efficient at
transducing human epithelial cells. Lentiviral vectors for use
in the invention may be derived from human and non-human
(including SIV) lentiviruses. Preferred lentiviral vectors
include nucleic acid sequences required for vector propagation as well as a tissue-specific promoter operably linked to,
for example, SEQ ID NO: 1, derivatives, variants and fragments thereof. These former may include the viral LTRs, a
primer binding site, a polypurine tract, att sites, and an
encapsidation site.
A lentiviral vector may be packaged into any suitable lentiviral capsid. The substitution of one particle protein with
another from a different virus is referred to as "pseudotyping". The vector capsid may contain viral envelope proteins
from other viruses, including murine leukemia virus (MLV)
or vesicular stomatitis virus (VSV). The use of the VSV
G-protein yields a high vector titer and results in greater
stability of the vector virus particles.
Alphavirus-based vectors, such as those made from semliki forest virus (SFV) and sindbis virus (SIN), might also be
used in the invention. Use of alphaviruses is described in
Lundstrom, K., Intervirology 43:247-257, 2000 and Perri et
al., Journal ofVirology 74:9802-9807, 2000. Alphavirus vectors typically are constructed in a format known as a rep Ii con.
A rep Ii con may contain (1) alphavirus genetic elements
required for RNA replication, and (2) a heterologous nucleic
acid such as one encoding SEQ ID NO: 1. Within an alphavirus replicon, the heterologous nucleic acid may be operably
linked to a tissue-specific promoter or enhancer.
Recombinant, replication-defective alphavirus vectors are
advantageous because they are capable of high-level heterologous (therapeutic) gene expression, and can infect a wide
host cell range. Alphavirus replicons may be targeted to specific cell types by displaying on their virion surface a functional heterologous ligand or binding domain that would
allow selective binding to target cells expressing a cognate
binding partner. Alphavirus replicons may establish latency,
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and therefore long-term heterologous nucleic acid expression
in a host cell. The replicons may also exhibit transient heterologous nucleic acid expression in the host cell. A preferred
alphavirus vector or replicon is non-cytopathic.
In many of the viral vectors compatible with methods of the
invention, more than one promoter can be included in the
vector to allow more than one heterologous gene to be
expressed by the vector. Further, the vector can comprise a
sequence which encodes a signal peptide or other moiety
which facilitates the secretion of a gene product from the host
cell.
To combine advantageous properties of two viral vector
systems, hybrid viral vectors may be used to deliver a nucleic
acid to a target tissue. Standard techniques for the construction of hybrid vectors are well-known to those skilled in the
art. Such techniques can be found, for example, in Sambrook,
et al., In Molecular Cloning: A laboratory manual. Cold
Spring Harbor, N.Y. or any numberoflaboratory manuals that
discuss recombinant DNA technology. Double-stranded
AAV genomes in adenoviral capsids containing a combination of AAV and adenoviral lilts may be used to transduce
cells. In another variation, anAAV vector may be placed into
a "gutless", "helper-dependent" or "high-capacity" adenoviral vector. Adenovirus/AAV hybrid vectors are discussed in
Lieber et al., J. Viral. 73:9314-9324, 1999. Retrovirus/adenovirus hybrid vectors are discussed in Zheng et al., Nature
Biotechnol. 18: 176-186, 2000. Retroviral genomes contained
within an adenovirus may integrate within the host cell
genome and effect stable urease gene expression.
Other nucleotide sequence elements which facilitate
expression of SEQ ID NO: 1, derivatives, variants and fragments thereof and cloning of the vector are further contemplated. For example, the presence of enhancers upstream of
the promoter or terminators downstream of the coding region,
for example, can facilitate expression.
In an aspect of the method wherein the viral expression
vector is anAAV vector capable of transducing the target cell,
the AAV vector is free of both wildtype and helper virus.
Exemplary types of AAV vectors useful in the present invention include serotype 2 AAV vectors and chimeric serotype 1h
AAV vectors.
2) Other Delivery Vehicles
Many nonviral techniques for the delivery of a nucleic acid
sequence into a cell can be used, including direct naked DNA
uptake (e.g., Wolff et al., Science 247: 1465-1468, 1990),
receptor-mediated DNA uptake, e.g., using DNA coupled to
asialoorosomucoid which is taken up by the asialoglycoprotein receptor in the liver (Wu and Wu, J. Biol. Chem. 262:
4429-4432, 1987; Wu et al., J. Biol. Chem. 266: 1433814342, 1991), and liposome-mediated delivery (e.g., Kaneda
eta!., Expt. Cell Res. 173: 56-69, 1987; Kanedaetal., Science
243: 375-378, 1989; Zhu et al., Science 261: 209-211, 1993).
Many of these physical methods can be combined with one
another and with viral techniques; enhancement ofreceptormediated DNA uptake can be effected, for example, by combining its use with adenovirus (Curiel et al., Proc. Natl. Acad.
Sci. USA 88: 8850-8854, 1991; Cristiano et al., Proc. Natl.
Acad. Sci. USA 90: 2122-2126, 1993). Other examples
include stem cells such as mesenchymal stem cells, hematopoietic stem cells, cardiac stem cells or neural stem cells,
embryonic stem cells that have been engineered to express
MCPIP. Such stem cells can be administered in such a way to
be incorporated in to tissues of a patient in need. In a particular embodiment, stem cells are administered to myocardial
tissue. Bu L, et al "Human ISL! heart progenitors generate
diverse multipotent cardiovascular cell lineages" Nature
2009 460:113-117.

Polynucleotides and Polypeptides
Aspects of the invention therefore include polynucleotides
encoding at least one mammalian MCPIP and amino acid
sequences representing at least one MCPIP protein. Aspects
of the invention also include subunits or variants of polynucleotides or MCPIP proteins or peptides encoded by those
polynucleotides. The terms "protein" and "polypeptide" are
used interchangeably herein, unless specified otherwise.
It is well known in the art that a single amino acid may be
encoded by more than one nucleotide codon-and that the
nucleotide sequence may be easily modified to produce an
alternate nucleotide sequence that encodes the same peptide.
Therefore, alternate embodiments of the present invention
include alternate DNA sequences encoding peptides containing the amino acid sequences described for MCPIP. DNA
sequences encoding peptides containing the claimed amino
acid sequence include DNA sequences which encode any
combination of the claimed sequence and any other amino
acids located N-terminal or C-terminal to the claimed amino
acid sequence.
It is to be understood that amino acid and nucleic acid
sequences may include additional residues, particularly N- or
C-terminal amino acids or 5' or 3' nucleotide sequences, and
still be essentially as set forth in the sequences disclosed
herein, as long as the sequence produces a functionally similar polypeptide or protein. A nucleic acid fragment of almost
any length may be employed, and may be combined with
other DNA sequences, such as promoters, polyadenylation
signals, additional restriction enzyme sites, multiple cloning
sites, other coding segments, and the like. Therefore, overall
length may vary considerably.
MCPIP polypeptides, as used herein, may comprise short
fragments of proteins often referred to as peptides, as well as
longer fragments generally referred to as polypeptides, and
full-length proteins. These polypeptides can be prepared by
standard peptide synthesis methods known to those of skill in
the art, but may also be produced using an expression vector
having a polynucleotide sequence encoding the polypeptide
(s) of choice operably linked to appropriate promoter, terminator, and other functional sequences (such as a sequence
encoding a purification tag) to facilitate expression and purification of the peptides.
It is to be understood that amino acid and nucleic acid
sequences may include additional residues, particularly N- or
C-terminal amino acids or 5' or 3' nucleotide sequences, and
still be essentially as set forth in the sequences disclosed
herein, as long as the sequence confers MCP-1 inducible
transcription factor activity upon the polypeptide or protein
moiety of the expressed protein. Nucleic acids which hybridize with a nucleic acid encoding the amino acid sequence of
SEQ ID NO: 2 or SEQ ID NO: 4 under stringent conditions
and encode a polypeptide having a similar MCP-1 inducible
transcription factor activity to that of a polypeptide comprising SEQ ID NO: 2 or SEQ ID NO: 4 are also included as
embodiments of the present invention.
The term "moderately stringent conditions", as used
herein, means conditions in which non-specific hybridization
will not generally occur. Hybridization under such conditions
can be performed based on the description provided in
Molecular Cloning: A Laboratory Manual 2nd ed., published
by cold Spring Harbor Laboratory in 1989, edited by T.
Maniatis et al. Typically, for stringent hybridization conditions a combination of temperature and salt concentration
should be chosen that is approximately 12-20° C. below the
calculated Tm of the hybrid under study. The Tm of a hybrid
between a polynucleotide of interest or the complement
thereof and a polynucleotide sequence which is at least about
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50, preferably about 75, 90, 96, or 98% identical to one of
those nucleotide sequences can be calculated, for example,
using the equation of Bolton and McCarthy, Proc. Natl. Acad.
Sci. U.S.A. 48, 1390 (1962):

Those of skill in the art may also make substitutions in the
amino acid sequence based on the hydrophilicity index or
hydropathic index of the amino acids. A variant amino acid
molecule of the present invention, therefore, has less than one
hundred percent, but at least about fifty percent, and preferably at least about eighty to about ninety percent amino acid
sequence homology or identity to the amino acid sequence of
a polypeptide comprising SEQ ID NO: 2, or a polypeptide
encoded by SEQ ID NO: 4. Therefore, the amino acid
sequence of the variant MCPIP protein corresponds essentially to the native MCPIP protein amino acid sequence. As
used herein, "corresponds essentially to" refers to a polypeptide sequence that will elicit a similar biological and enzymatic activity to that generated by a MCPIP protein comprising SEQ ID NO 2 or SEQ ID NO: 4, such activity being at
least about 70 percent that of the native MCPIP protein, and
more preferably greater than 90 percent of the activity of the
native MCPIP protein.
A variant of the MCPIP protein may include amino acid
residues not present in a corresponding MCPIP protein comprising SEQ ID NO 2, or may include deletions relative to the
MCPIP protein comprising SEQ ID NO 2. A variant may also
be a truncated "fragment," as compared to the corresponding
protein comprising SEQ ID NO 2, the fragment being only a
portion of the full-length protein.
Polypeptides of the invention may be delivered to a cell via
attachment of one or more polypeptides to cell permeable, or
"importation competent" signal peptide sequences, and
membrane translocation sequences that have been shown to
facilitate the transport of attached peptides and proteins into
cells. Several sequences of this kind have previously been
described, including the hydrophobic region of the signal
sequence of Kaposi fibroblast growth factor which has been
fused to the nuclear localization sequence (NLS) of p50 to
producethepeptideknownas SN50 (U.S. Pat. No. 5,807,746,
Lin et al.). Polypeptides may also be delivered via a membrane translocating sequence described in U.S. Pat. Nos.
6,248,558; 6,432,680; and 6,780,843 (Rojas et al.). MCPIP,
or a nuclear localization sequence that blocks nuclear localization ofMCPIP, may also be delivered via the cell-permeable sequence described in U.S. Patent Application Number
20060099275 (Lin and Budu). Other membrane-translocating sequences are also well-known to those of skill in the art.
Non-invasive delivery of proteins via membrane translocating peptides is discussed by Hawiger in Curr. Opin Chem.
(1999) 3: 89-94, and multiple examples of both in vitro and in
vivo use of membrane translocation via cell-permeable peptide sequences are available in the literature. The HIV-Tat
peptide, for example, has been used in a number of studies to
deliver cargo peptides to target cells (Ribeiro, M. M., et al.
Biochem. Biophys. Res. Commun. (2003) 305(4): 876-81;
Jung, H.J., et al. Biochem. Biophys. Res. Commun. (2006)
345(1): 222-228; Barnett, E. M., et al. Invest. Ophthalmol.
Vis. Sci. (2006) 47(6): 2589-2595; Hoque, M., et al. J. Biol.
Chem. (2005) 280(14): 13648-13657; Monda! D., et al. Exp.
Biol. Med. (2005) 230(9): 631-644; Kittiworakam, J., et al. J.
Biol. Chem. (2006) 281(6): 3105-3115).
Polynucleotides encoding all or a part of the amino acid
sequence ofMCPIP may be delivered in vitro or in vivo by a
variety of means known to those of skill in the art, such as, for
example, viral gene delivery, naked DNA, delivery via cationic lipid carriers, and plasmid DNA/poly lysine complexes.
As used herein, MCPIP polypeptides include variants or
biologically active fragments of the peptides, as well as peptides which may contain additional amino acids either N-terminal or C-terminal (or both) to the disclosed sequences, their
derivatives, variants, or functional counterparts. A "func-

Tm ~81.5° C.-16.6(log 10 [Na•])+0.41(%G+C)-0.63
(%formamide)-600/l),

where I=the length of the hybrid in basepairs.
Stringent wash conditions include, for example, 4xSSC at
65° C., or 50% formamide, 4xSSC at 42° C., or 0.5xSSC,
0.1 % SDS at 65° C. Highly stringent wash conditions include,
for example, 0.2xSSC at 65° C. According to another
example, stringent conditions include incubation with a probe
in 6xSSC containing 0.5% SDS, 5xDenhardt's solution and
100 micrograms/ml salmon sperm DNA at 60 degrees C.
Additional nucleic acid bases may be added either 5' or 3'
to the MCPIP ORF, and may be combined with other DNA
sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other
coding segments, and the like. Therefore, overall length of
such a polynucleotide may vary considerably. In a method
described by the present invention, a nucleotide sequence of
SEQ ID NO: 1 is inserted into a protein expression vector to
produce a protein which can be used to synthesize a DNA
copy of an RNA molecule. The DNA can then be amplified to
form multiple copies.
"Control sequences" are those DNA sequences that are
necessary for the expression of a protein from a polynucleotide sequence containing such a sequence, operably linked
to the polynucleotide sequence encoding the protein. These
sequences include prokaryotic sequences such as, for
example, promoters, operators, and ribosome binding sites,
and eukaryotic sequences such as, for example, promoters,
enhancers, and polyadenylation signals. "Expression systems" are DNA sequences (such as, for example, plasmids)
appropriate for expression of a target protein in a particular
host cell, these sequences comprising appropriate control
sequences for protein expression in the host cell operably
linked to the polynucleotide sequence encoding the target
protein.
It is to be understood that a "variant" of a polypeptide is not
completely identical to the native protein. A variant MCPIP
protein, for example, can be obtained by altering the amino
acid sequence by insertion, deletion or substitution of one or
more amino acids. The amino acid sequence of the protein can
be modified, for example, by substitution to create a polypeptide having substantially the same or improved qualities as
compared to the native polypeptide. The substitution may be
a conserved substitution. A "conserved substitution" is a substitution of an amino acid with another amino acid having a
side chain that is similar in polar/nonpolar nature, charge, or
size. The 20 essential amino acids can be grouped as those
having nonpolar side chains (alanine, valine, leucine, isoleucine, praline, phenylalanine, and tryptophan), uncharged
polar side chains (methionine, glycine, serine, threonine, cystine, tyrosine, asparagine and glutamine), acidic side chains
(aspartate and glutamate), and basic side chains (lysine, arginine, and histidine). Conserved substitutions might include,
for example, Asp to Glu, Asn, or Gin; His to Lys, Arg or Phe;
Asn to Gin, Asp or Glu; and Ser to Cys, Thr or Gly. Alanine,
for example, is often used to make conserved substitutions.
To those of skill in the art, variant polypeptides can be
obtained by substituting a first amino acid for a second amino
acid at one or more positions in the polypeptide structure in
order to affect biological activity. Amino acid substitutions
may, for example, induce conformational changes m a
polypeptide that result in increased biological activity.
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tional counterpart" can include, for example, a peptide
nucleic acid (PNA). A "variant" of the peptide is not completely identical to a disclosed MCPIP polypeptide sequence.
A variant, given the disclosure of the present invention, can be
obtained by altering the amino acid sequence by insertion,
deletion or substitution of one or more amino acid. The amino
acid sequence of a disclosed peptide can be modified, for
example, by substitution to create a peptide having substantially the same or improved qualities. The substitution may be
a conserved substitution. A "conserved substitution" is a substitution of an amino acid with another amino acid having a
side chain that is similar in polar/nonpolar nature, charge, or
size. The 20 essential amino acids can be grouped as those
having nonpolar side chains (alanine, valine, leucine, isoleucine, praline, phenylalanine, and tryptophan), uncharged
polar side chains (methionine; glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine), acidic side chains
(aspartate and glutamate) and basic side chains (lysine, arginine, and histidine). Conserved substitutions might include,
for example, Asp to Glu, Asn or Gin; His to Lys, Arg or Phe;
Asn to Gin, Asp or Glu, Leu to Ile or Val, and Ser to Cys, Thr
or Gly. Alanine is commonly used to make conserved substitutions.
To those of skill in the art, variant polypeptides can be
obtained by substituting a first amino acid for a second amino
acid at one or more positions in the peptide structure in order
to affect biological activity. Amino acid substitutions may, for
example, induce conformational changes in a polypeptide
that result in increased biological activity. Those of skill in the
art may also make substitutions in the amino acid sequence
based on the hydrophilicity index or hydropathic index of the
amino acids.
A variant polypeptide of the present invention has less than
100%, but at least about 50%, and more preferably at least
about 80% to about 90% amino acid sequence homology or
identity to the amino acid sequence of a corresponding native
nucleic acid molecule or polypeptide comprising SEQ ID NO
1, SEQ ID NO 2, SEQ ID NO 3, or SEQ ID NO 4. The amino
acid sequence of a variant MCPIP polypeptide therefore corresponds essentially to the disclosed amino acid sequences.
As used herein, "corresponds essentially to" refers to a
polypeptide sequence that will elicit a similar biological
activity as that generated by a disclosed MCPIP, such activity
being from at least about 70 percent of that of disclosed
MCPIP polypeptide, to greater than 100 percent of the activity of a disclosed MCPIP peptide.
The human MCPIP polypeptide sequence comprises a
Zc3h12a Ribonuclease domain at residues 130-280 and zinc
finger domain at 284-309. It is to be understood that nonconserved substitutions at these regions will likely result in
negating activity of the protein. Mizgalska et al., FEBS Journal 276:7386-7399 (2009). Conserved substitutions in these
domains will likely result in preserving activity of the protein.
Most mutations, whether conservative or non-conservative,
outside the two domains will not likely affect activity of the
protein to any great extent. Accordingly, the disclosure of
SEQ ID NO: 2 combined with the knowledge in the art
regarding the genetic code establishes possession of using the
genus of nucleic acid sequences that encode SEQ ID NO. 2, as
well as sequences that encode a polypeptide with at least 85
percent sequence identity with SEQ ID NO. 2.
A variant of a disclosed MCPIP may include amino acid
residues not present in the corresponding MCPIP, or may
include deletions relative to the corresponding MCPIP. A
variant may also be a truncated "fragment" as compared to the
corresponding MCPIP, i.e., only a portion of the amino acid
sequence of certain disclosed MCPIPs. The fragment may be

atleast20, 30, 40, 50, 60, 80, 90, 100, 150, 175, 200, 250, 300,
350, 400, 450, 500, 550, 560, 570, 580, 585, 590, or 595
amino acids in length.
Variants, including fragments, possessing activity of
MCPIP, refer to those, that are capable of degrading interleukin I-beta (see Mizgalska et al.). Alternatively, the variant has
activity according to the in vitro assay for transcription factor
activity as taught in Zhou et al., Circulation Research,
98: 1177-1185 (2006). Preferably, naturally or non-naturally
occurring polypeptide variants have amino acid sequences
which are at least about 55, 60, 65, or 70, preferably about 75,
80, 85, 90, 96, 96, or 98% identical to the full-length amino
acid sequence or a fragment thereof. Percent identity between
a putative polypeptide variant and a full length amino acid
sequence is determined using the Blast2 alignment program
(Blosum62, Expect 10, standard genetic codes).
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EXAMPLES
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Example 1
Expression ofMCPIP on Scratch-Induced Wound
Healing in HaCaT Cells
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Cells were cultured to confluence and transfected with
GFP or MCPIP vectors for 48 hrs and wounded by scratching.
Cells were then incubated for the indicated hours and photographed. See FIG. lA. The scratch induced wound healing
during 24 hrs after scratching was then quantified. The wound
distance was quantified and it was shown enhanced expression of MCPIP caused a significant decrease in wound distance. This was correlated with HaCAt cell migration. see
FIG. lB.
Example 2
Knockdown of MCPIP Inhibited Migration of
HaCaT Cells
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HaCaT cells were cultured and transfected with MCPIP
siRNA or non-targeted siRNA for 48 hrs. RT-PCR was performed to confirm that siRNA efficiently knockdown of
MCPIP mRNA levels. FIG. 2A is a photograph of a gel of
RT-PCR samples showing that MCPIP siRNA efficiently
knocks down MCPIP. HaCaT Cells were cultured to confluence and wounded by scratching. Cells were then incubated
for 0, 12, and 24 hours and then photographed (FIG. 2b).
Migration of the cells proximate to the scratch wound was
measured at 24 hours. FIG. 2C shows that HaCaT cells transfected with MCPIP siRNA show a significant decrease in
migration.
Example 3
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Lack ofMCPIP Impaired Wound Healing in MCPIP
KO Mice
(A) Wounds were formed on the epidermis ofMCPIP KO
mice and wild type mic. Wound sites were photographed at
day 7 and day 12. FIG. 3A clearly shows that the level of
wound healing in the MCPIP knockout mice is significantly
less in as compared to wild-type. Changes in percentage of
wound area at the day 7 and day 12 time points of the knockout and wild-type mice were compared with the original
wound area. The percentage of the wound area at day 7 and 12
is dramatically greater in the knockout mice as compared to
wild-type (FIG. 3C).

US 8,999,314 B2
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Example 4

Numerous variations, changes and substitutions may be made
without departing from the invention herein. Accordingly, it
is intended that the invention be limited only by the spirit and
scope of the appended claims. The teachings of all patents and
other references cited herein are incorporated herein by reference in their entirety to the extent they are not inconsistent
with the teachings herein.

Expression of MCPIP Enhanced Wound Healing in
Diabetic Mice
Induction ofMCPIP was found in the wound skin but not in
the healed skin (see FIG. 4). As shown in FIG. 4(B), wound
sites were photographed at day 0, 3, 7 and 12. Day Opictures
were taken immediately after the wound. Changes in percentage of wound area at each time point compared with the
original wound area, which is shown in FIG. 4C. The level of
healing in the MCPIP enhanced animals is clearly greater
than the control. FIG. 4D shows the expression of cytokines in
wound skins at day 12 after wound. Expression of PECAM
and VEFF in wound skins at day 12 was examined by RT-PCR
(see FIG. 4F).
Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art of molecular biology.
Although methods and materials similar or equivalent to
those described herein can be used in the practice or testing of
the present invention, suitable methods and materials are
described herein. All publications, patent applications, patents, and other references mentioned herein are incorporated
by reference in their entirety. In case of conflict, the present
specification, including definitions, will control. In addition,
the materials, methods, and examples are illustrative only and
are not intended to be limiting.
Reference is made to standard textbooks of molecular biology that contain definitions and methods and means for carrying out basic techniques, encompassed by the present
invention. See, for example, Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory
Press, New York (1982) and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory
Press, New York (1989); Methods in Plant Molecular Biology, Maliga et al, Eds., Cold Spring Harbor Laboratory Press,
New York (1995); Arabidopsis, Meyerowitz et al, Eds., Cold
Spring Harbor Laboratory Press, New York (1994) and the
various references cited therein.
Finally, while various embodiments of the present invention have been shown and described herein, it will be obvious
that such embodiments are provided by way of example only.
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What is claimed is:
1. A topical composition for application to a wound in a
subject to promote healing of the wound, the wound composition comprising:
an effective amount ofMCPIP polypeptide for treatment of
the wound; and
a pharmaceutically acceptable carrier in a form configured
for topical administration to the subject.
2. The topical composition of claim 1, which is in a form
selected from the group consisting of a solution, a suspension,
a spray, a cream, a gel, a foam, an ointment, a lotion, and a
powder.
3. The topical composition of claim 1, wherein the pharmaceutically acceptable carrier comprises a dressing, the
dressing selected from the group consisting of a transdermal
patch, a pad, a powder, a matrix, and a bandage.
4. A kit comprising:
a pharmaceutical composition comprising an effective
amount of MCPIP for treating a wound and a pharmaceutically acceptable carrier; and
instructions directing a user to use of the pharmaceutical
composition in the treatment of a wound in a subject.
5. The kit of claim 4, wherein the wound is at least one of
a wound selected from the group consisting of an incomplete
healing wound, a chronic wound, a bum, and a wound caused
by trauma.
. ~· T~e. kit of claim 4, wherein the pharmaceutical compos1t10n 1s m a form from the group consisting of a solution, a
suspension, a spray, a cream, a gel, a foam, an ointment, a
lotion, or a powder.
7. The kit of claim 4, wherein the pharmaceutically acceptable carrier comprises a dressing, the dressing selected from
the group consisting of a transdermal patch, a pad, a powder,
a matrix, and a bandage.
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